Comparative Pharmacology
Head-to-head clinical analysis: ASACOL versus DIPENTUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASACOL versus DIPENTUM.
ASACOL vs DIPENTUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Asacol (mesalamine) is an aminosalicylate that exerts anti-inflammatory effects in the colon via inhibition of prostaglandin and leukotriene synthesis, particularly by blocking cyclooxygenase and lipoxygenase pathways, and by scavenging reactive oxygen species. It also inhibits cytokine production and reduces mucosal inflammation.
Olsalazine is a prodrug that is activated in the colon by bacterial azoreductases to release two molecules of 5-aminosalicylic acid (mesalamine), which locally inhibits cyclooxygenase and lipoxygenase pathways, reducing prostaglandin and leukotriene production, and exerts anti-inflammatory effects in the colonic mucosa.
800 mg orally three times daily or 1600 mg three times daily for 6 weeks; maintenance: 1.6 g daily in divided doses.
500 mg orally twice daily, administered as two 250 mg capsules.
None Documented
None Documented
Terminal half-life: 0.6-1.4 hours for 5-ASA; 6-12 hours for N-acetyl-5-ASA. Clinical context: short t1/2 necessitates multiple daily dosing for sustained colonic exposure.
Terminal elimination half-life of olsalazine is approximately 0.9 hours. The active metabolite, 5-ASA, has a half-life in the colon of 2-5 hours due to local retention; systemic half-life is short (0.6-1.4 hours).
Renal (80% as 5-ASA and N-acetyl-5-ASA), fecal (20%)
Primarily renal (80%), with fecal/biliary excretion up to 20% as olsalazine and metabolites (mainly 5-ASA).
Category C
Category C
Aminosalicylate
Aminosalicylate